摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(-)-(S)-N-(alpha-Ethylbenzyl)-3-(carboxymethoxy)-2-phenylquinoline-4-carboxamide | 224961-34-6

中文名称
——
中文别名
——
英文名称
(-)-(S)-N-(alpha-Ethylbenzyl)-3-(carboxymethoxy)-2-phenylquinoline-4-carboxamide
英文别名
2-[2-phenyl-4-[[(1S)-1-phenylpropyl]carbamoyl]quinolin-3-yl]oxyacetic acid
(-)-(S)-N-(alpha-Ethylbenzyl)-3-(carboxymethoxy)-2-phenylquinoline-4-carboxamide化学式
CAS
224961-34-6
化学式
C27H24N2O4
mdl
——
分子量
440.5
InChiKey
RJIWGNBRTQFKBW-NRFANRHFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    33
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    88.5
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE
    申请人:Kyushu University, National University Corporation
    公开号:EP3881843A1
    公开(公告)日:2021-09-22
    A prophylactic or therapeutic agent for an IL-31 mediated disease, said agent comprising a neurokinin B signal blocker.
    一种 IL-31 介导疾病的预防或治疗药物,所述药物包括神经激肽 B 信号阻断剂。
  • ANTI-ANDROGENS AND METHODS FOR TREATING DISEASE
    申请人:SMITHKLINE BEECHAM CORPORATION
    公开号:EP1146873A1
    公开(公告)日:2001-10-24
  • EP1146873A4
    申请人:——
    公开号:EP1146873A4
    公开(公告)日:2003-03-26
  • [EN] ANTI-ANDROGENS AND METHODS FOR TREATING DISEASE<br/>[FR] ANTI-ANDROGENES ET PROCEDES DE TRAITEMENT
    申请人:SMITHKLINE BEECHAM CORP
    公开号:WO2000043008A1
    公开(公告)日:2000-07-27
    The present invention is the novel use of NK-3 receptor antagonist compounds for the treatment and/or prophylaxis of diseases which are caused by high or inappropriate levels of gonadotropins and/or androgens, particularly testosterone.
  • [EN] NOVEL USE<br/>[FR] NOUVELLE UTILISATION
    申请人:SMITHKLINE BEECHAM CORP
    公开号:WO2002040023A1
    公开(公告)日:2002-05-23
    A method for the treatment or prophylaxis of the common cold, or respiratory viral infection caused by human rhinovirus infection (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus infection in a human in need thereof, which method comprises administering to said human an effective amount of an NK3 antagonist.
查看更多